Abstract
Hereditary amyloidogenic transthyretin (TTR) (ATTR) amyloidosis is an autosomal dominant form of fatal hereditary amyloidosis. Owing to progress in biochemical and molecular genetic analyses, this disease is now believed to occur worldwide. As of today, reports of about 120 different points of single or double mutations, or a deletion in the TTR gene have been reported, and several different phenotypes of ATTR amyloidosis have been documented. In addition, since liver transplantation has been established to halt the progression of hereditary ATTR amyloidosis in the early stage, rapid and reliable diagnostic system for ATTR amyloidosis is needed. On the other hand, senile systemic amyloidosis (SSA) derived from wild-type (WT) TTR affects primarily in the heart and lungs and occasionally in carpal ligaments in the elderly. To perform accurate diagnosis and effective treatments, we should distinguish between hereditary ATTR amyloidosis and SSA by means of genetic and proteomic analyses.
The liver transplantation for hereditary ATTR amyloidosis has become a well-established treatment, because the main source of serum variant TTR is shut out. However, this treatment has several problems, such as expensive medical costs, lifelong administration of immunosuppressants, non-indication for the mutated-TTR gene carriers without clinical symptoms, shortage of liver donors, and further development of cardiac and ocular disorders. Therefore, we and other ATTR amyloidosis research groups have been investigating the possibility of stabilization of variant TTR, gene therapy, and immunotherapy for ATTR amyloidosis on the basis of TTR amyloid formation mechanism.
We present here the current diagnostic procedure and therapeutic approaches for the disease.
Keywords: Amyloidosis, ATTR amyloidosis, gene therapy, immunotherapy, senile systemic amyloidosis, transthyretin, Hereditary, amyloidogenic transthyretin, autosomal dominant, biochemical and molecular genetic
Current Medicinal Chemistry
Title:Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Volume: 19 Issue: 15
Author(s): Y. Ando, M. Ueda
Affiliation:
Keywords: Amyloidosis, ATTR amyloidosis, gene therapy, immunotherapy, senile systemic amyloidosis, transthyretin, Hereditary, amyloidogenic transthyretin, autosomal dominant, biochemical and molecular genetic
Abstract: Hereditary amyloidogenic transthyretin (TTR) (ATTR) amyloidosis is an autosomal dominant form of fatal hereditary amyloidosis. Owing to progress in biochemical and molecular genetic analyses, this disease is now believed to occur worldwide. As of today, reports of about 120 different points of single or double mutations, or a deletion in the TTR gene have been reported, and several different phenotypes of ATTR amyloidosis have been documented. In addition, since liver transplantation has been established to halt the progression of hereditary ATTR amyloidosis in the early stage, rapid and reliable diagnostic system for ATTR amyloidosis is needed. On the other hand, senile systemic amyloidosis (SSA) derived from wild-type (WT) TTR affects primarily in the heart and lungs and occasionally in carpal ligaments in the elderly. To perform accurate diagnosis and effective treatments, we should distinguish between hereditary ATTR amyloidosis and SSA by means of genetic and proteomic analyses.
The liver transplantation for hereditary ATTR amyloidosis has become a well-established treatment, because the main source of serum variant TTR is shut out. However, this treatment has several problems, such as expensive medical costs, lifelong administration of immunosuppressants, non-indication for the mutated-TTR gene carriers without clinical symptoms, shortage of liver donors, and further development of cardiac and ocular disorders. Therefore, we and other ATTR amyloidosis research groups have been investigating the possibility of stabilization of variant TTR, gene therapy, and immunotherapy for ATTR amyloidosis on the basis of TTR amyloid formation mechanism.
We present here the current diagnostic procedure and therapeutic approaches for the disease.
Export Options
About this article
Cite this article as:
Y. Ando, M. Ueda , Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis, Current Medicinal Chemistry 2012; 19 (15) . https://dx.doi.org/10.2174/092986712800269317
DOI https://dx.doi.org/10.2174/092986712800269317 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ocular Complications of Drugs Used in Rheumatic Disease
Current Rheumatology Reviews Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Intraocular Delivery of Anti-Infective Drugs-Bacterial, Viral, Fungal and Parasitic
Recent Patents on Anti-Infective Drug Discovery Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Moving Object Detection in Spatial Domain using Background Removal Techniques - State-of-Art
Recent Patents on Computer Science Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design Traumatic Spinal Cord Injury Alters Angiogenic Factors and TGF-Beta1 that may Affect Vascular Recovery
Current Neurovascular Research